Overview

ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a Week

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine the satisfaction of subject with Actonel 35 mg Once a Week in the treatment of post-menopausal osteoporosis. Open, non-controlled, multi-center study.
Phase:
Phase 4
Details
Lead Sponsor:
Sanofi
Collaborator:
Procter and Gamble
Treatments:
Risedronate Sodium
Risedronic Acid